Mike Hunter said the New Jersey-based company and its subsidiaries, including Janssen Pharmaceuticals, created a public nuisance by launching a “cunning, cynical and deceitful” marketing campaign that overstated the benefits of opioid drugs for treating chronic pain and understated the risk of addiction. “There was a simple reason for the crisis: greed,” Hunter said. “The greed of the pharmaceutical companies caused the crisis.” After closing arguments, Cleveland County District Judge Thad Balkman asked both sides to present written summaries of their cases by July 31 and said that he would then take about a month to issue his ruling. Oklahoma’s case is being closely watched because it’s the first state case to proceed to trial. It could help shape negotiations over roughly 1,500 similar lawsuits filed by state, local and tribal governments that have been consolidated before a federal judge in Ohio. Attorneys for Johnson & Johnson argued they participated in a lawful and strictly regulated industry and that their marketed products represented only a tiny fraction of the opioids used in Oklahoma. Oklahoma’s attorneys have pointed out that two former Johnson & Johnson subsidiaries, Noramco and Tasmanian Alkaloids, produced much of the raw opium that is used by other manufacturers to produce the drugs. Larry Ottaway, an attorney for the company, said opioid drugs serve a critical health need — to address chronic pain that affects thousands of Oklahomans every day. “This problem of untreated chronic pain afflicts people here in Oklahoma,” Ottaway said. “These drugs help these patients function.” During his closing argument, Ottaway played brief clips from a half-dozen Oklahoma doctors who testified about the desperate need some of their patients have to deal with chronic pain. “I trust you to do the right thing,” Ottaway told the judge. “I trust you like I trust these Oklahoma doctors, and I think you should trust them as well.” Attorneys for Oklahoma also outlined a plan developed by state mental health and addiction specialists to abate the opioid crisis that would range between $12.6 billion for 20 years or $17.5 billion over 30 years. Attorneys for Johnson & Johnson say that estimate is wildly overinflated. Included in the abatement estimate is a need for the state of Oklahoma to hire 1,734 new employees at a cost of about $123 million each year, Ottaway said. “The state’s plan is simply untenable,” he said. “It seeks billions of dollars for services already being provided.” Before the start of the trial on May 28, Oklahoma reached a $270 million settlement with Oxycontin-maker Purdue Pharma and an $85 million deal with Israeli-owned Teva Pharmaceutical Industries Ltd. ___ Follow Sean Murphy at www.twitter.com/apseanmurphy ___ This version corrects the spelling of the last name of Johnson & Johnson attorney Larry Ottaway.
Oklahoma AG calls company ‘kingpin’ in state’s opioid crisis.